Effects of probucol on angiotensin II-induced BMP-2 expression in human umbilical vein endothelial cells

MING ZHANG*, JIAN WANG*, JING-HUA LIU, SHU-JUAN CHEN, BIN ZHEN, CHANG-HUA WANG, HUA HE and CHEN-XI JIANG

Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Sciences, Beijing 100029, P.R. China

Received May 4, 2012; Accepted August 29, 2012

DOI: 10.3892/mmr.2012.1145

Abstract. Bone morphogenetic protein-2 (BMP-2) participates significantly in vascular development and pathophysiological processes. Angiotensin II (AngII) has been demonstrated to be critical in the initiation and progression of atherosclerosis. However, the effects of AngII on BMP-2 expression and of probucol on the AngII-induced BMP-2 expression in human umbilical vein endothelial cells (HUVECs) are unknown. The aim of our study was to investigate these effects. HUVECs were cultured and stimulated with various agents. The total superoxide dismutase (SOD) activity and the concentrations of malondialdehyde (MDA) and BMP-2 were measured by standard methods. Northern blotting was used to detect the expression of BMP-2 mRNA. The activation of NF-κB in the HUVECs was also determined. The AngII treatment significantly increased BMP-2 expression levels and activated NF-κB. These effects were suppressed by treatment with pyrrolidine dithiocarbamate (PDTC) or probucol. Furthermore, the increased levels of MDA in the conditioned medium and the decrease in the total SOD activity caused by the AngII treatment were reversed by treatment with probucol or PDTC. Probucol downregulated the AngII-induced BMP-2 expression. These effects of probucol may be mediated by the inhibition of NF-κB activation.

Introduction

Previous studies have shown that bone morphogenetic protein-2 (BMP-2), a transforming growth factor-β superfamily member cytokine, participates significantly in vascular development and pathophysiological processes (1,2). Vascular endothelial and smooth muscle cells are a significant source of BMPs (3,4). BMP-2 induction in blood vessels may be related to oxidative stress, vascular inflammatory response, hyperglycemia and hyperlipidemia (5,6). Angiotensin II (AngII), the main effector of the renin-angiotensin system, is essential for the regulation of blood pressure and is also involved in arterial wall remodeling (7,8). The inhibition of the renin-angiotensin-aldosterone system has beneficial effects on endothelial functioning in animals and humans (9-11). The aim of this study was to investigate whether AngII induces BMP-2 expression. Furthermore, we also examined the effects of probucol, a cholesterol-lowering drug with potent antioxidative properties which attenuates atherosclerosis in animals and humans (12,13), on the AngII-induced BMP-2 expression.

Materials and methods

Human umbilical vein endothelial cell (HUVEC) culture and treatment. HUVECs and supplements, purchased from Cascade Biologics (Portland, OR, USA), were grown in Medium 200 with low serum growth supplement (LSGS) on polystyrene plates until 90% confluent. Non-adhering cells were poured off and the adhering cells were incubated at 37˚C under an atmosphere of 5% CO₂ and 95% air. After 3-5 days, the cultures formed a confluent monolayer and were subcultured. The cells were used at passages 5-7. The cells were cultured at 1x10⁶ cells/25 cm² flask and then were divided into 7 groups: a control group (treated with medium only); a probucol group (treated with 10 µmol/l probucol); a PDTC group (treated with 15 µmol/l PDTC); 2 AngII groups (treated with 0.1 and 1.0 µmol/l AngII, respectively); an AngII + PDTC group (treated with 1.0 µmol/l AngII plus 15 µmol/l PDTC); and an AngII + probucol group (treated with 1.0 µmol/l AngII plus 10 µmol/l probucol). The combination treatment groups were pretreated with 15 µmol/l PDTC or 10 µmol/l probucol for 6 h prior to the administration of AngII.

BMP-2 mRNA expression by northern blot analysis. Total cellular RNA was isolated from the HUVECs using the TRizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Northern blot analysis was performed as previously described (11). RNA blots were hybridized overnight at 57°C in a hybridization oven with [α-32P]dATP-labeled oligonucleotide probes for BMP-2 or the cDNA for β-actin. The blots were then washed, air dried and exposed.
Measurement of malondialdehyde (MDA) and BMP-2 concentrations in culture medium and total superoxide dismutase (SOD) activity in cell lysates. The concentrations of MDA were determined as thiobarbituric acid-reactive substances. The total activity of SOD was determined using the SOD Assay kit-WST according to the manufacturer’s instructions. BMP-2 protein levels were measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions. Each sample was assayed in duplicate. The intra-assay and inter-assay precision variability was <8%.

Effects of administering agents on cytoplasmic and nuclear levels of NF-κB p65. The effects of various agents on the activation of NF-κB in HUVECs were determined using an assay kit from Active Motif (Carlsbad, CA, USA). This kit measures free p65, which is generated when NF-κB is activated. To obtain assay material, the cells were seeded at 1.0x10⁶ cells/25cm² flask. The cells were harvested 12 h after the addition of these agents. Cytoplasmic and nuclear cell fractions were collected using the reagents supplied in a nuclear extract kit (Active Motif). The cells were harvested by scraping and pelleted by centrifugation at 2,000 x g at 4°C for 75 sec. The pelleted cells were resuspended in 200 µl hypotonic buffer and incubated on ice for 15 min. Nonidet P-40 (Sigma, St. Louis, MO, USA), a solubilizing agent, was added and the cells were vortexed for 10 sec. The material was centrifuged for 45 s at 14,000 x g at 4°C. The supernatant fluids (cytoplasmic fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C. The resulting nuclear pellets were resuspended in the lysis buffer supplied in the kit and then vortexed for 10 sec. The suspension was incubated for 30 min on ice on a rocking platform, vortexed for 30 sec and then centrifuged at 14,000 x g for 10 min at 4°C. The supernatant fluids (nuclear fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C. To assay the nuclear and cytoplasmic samples for amounts of p65, 20 µl samples were added to the wells of a 96-well plate and coated with an oligonucleotide containing the NF-κB consensus binding site. The p65 subunit of the activated NF-κB contained in the cell extracts specifically binds to this oligonucleotide. The plate was incubated for 1 h at room temperature on a rocking platform. After washing, an antibody to p65 was added and the plate was incubated for 1 h at room temperature. The wells were then washed, an HRP-conjugated antibody was added and incubation was continued for 1 h at room temperature. After washing, a substrate solution was added to the wells and the plate was incubated at room temperature for 10 min, protected from light. A stop solution (2N H₂SO₄) was added and the absorbance at 450 nm was read. The amounts of protein in the fractions were determined by a modification of the method of Lowry et al (14,15). The results are expressed as A₄₅₀ nm/mg protein and expressed as a percentage (%) of the control (value for cells exposed to control medium, set at 100%).

Figure 1. Northern blotting for evaluation of BMP-2 mRNA. The bar graph shows mean values (± SEM) from the densitometric analysis of 7 treatment groups, n=8 per group. The groups are: 1, control; 2, PDTC; 3, probucol; 4, 0.1 µmol/l AngII; 5, 1.0 µmol/l AngII; 6, 1.0 µmol/l AngII + PDTC; and 7, 1.0 µmol/l AngII + probucol. *P<0.05 vs. control group. △P<0.05 vs. 1.0 µmol/l AngII + PDTC group, #P<0.05 vs. 1.0 µmol/l AngII + probucol group. BMP-2, bone morphogenetic protein-2; PDTC, pyrrolidine dithiocarbamate; AngII, angiotensin II.
bound to antibodies was detected by light microscopy and images were captured at x100. Samples from each group were graded for histopathological changes and immunohistochemistry staining. The intensity of the immunostaining was graded from 0 (no staining) to degree C (maximum staining).

Statistical analysis. All data are presented as the means ± SD. Multiple comparisons among groups were performed by one-way ANOVA analysis. \( P<0.05 \) was considered to indicate a statistically significant result.

**Results**

**Induction of BMP-2 expression in HUVECs.** The mRNA levels of BMP-2 in the HUVECs following the various treatments are shown in Fig. 1. Compared with the control group, AngII treatment led to a significant increase in the expression levels of BMP-2 mRNA; however, administration of PDTC or probucol significantly downregulated the AngII-induced BMP-2 expression (Fig. 1). BMP-2 and CuZnSOD protein expression were also detected by western blot analysis. Our results showed that CuZnSOD protein expression was downregulated by AngII treatment, but this downregulation was partially reversed by probucol or PDTC treatment (Fig. 2A and B).

**Effects of agents on NF-κB p65 levels in HUVECs.** NF-κB p65 activation was detected using immunohistochemistry and an assay kit from Active Motif. AngII caused a significant increase in nuclear p65 levels compared with those in the control group, reaching a maximum increase of ~5-fold following 1.0 \( \mu \)mol/l AngII treatment, but this was decreased by the administration of PDTC or probucol. In the cytoplasm

![Figure 2. Western blotting for evaluation of BMP-2 and SOD proteins. The bar graphs show mean values (± SEM) from the densitometric analysis of (A) BMP-2 expression and (B) SOD activity in the 7 treatment groups, n=8 per group. 1, control; 2, PDTC; 3, probucol; 4, 0.1 \( \mu \)mol/l AngII; 5, 1.0 \( \mu \)mol/l AngII; 6, 1.0 \( \mu \)mol/l AngII + PDTC; and 7, 1.0 \( \mu \)mol/l AngII + probucol groups. \( *P<0.05 \) vs. control group, \( \Delta P<0.05 \) vs. 1.0 \( \mu \)mol/l AngII + PDTC group, \( ﹟P<0.05 \) vs. 1.0 \( \mu \)mol/l AngII + probucol group. BMP-2, bone morphogenetic protein-2; SOD, superoxide dismutase; PDTC, pyrrolidine dithiocarbamate; AngII, angiotensin II.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Nuclear NF-κB p65 levels</th>
<th>Cytoplasmic NF-κB p65 levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>205±22</td>
<td>107±15</td>
</tr>
<tr>
<td>15 ( \mu )mol/l PDTC</td>
<td>210±19</td>
<td>113±14</td>
</tr>
<tr>
<td>10 ( \mu )mol/l probucol</td>
<td>207±25</td>
<td>108±13</td>
</tr>
<tr>
<td>0.1 ( \mu )mol/l AngII</td>
<td>529±49(^a)</td>
<td>213±21(^a)</td>
</tr>
<tr>
<td>1.0 ( \mu )mol/l AngII</td>
<td>1006±95(^{a,b,c})</td>
<td>335±25(^{a,b,c})</td>
</tr>
<tr>
<td>AngII + PDTC</td>
<td>308±27</td>
<td>190±20</td>
</tr>
<tr>
<td>AngII + probucol</td>
<td>312±28</td>
<td>204±18</td>
</tr>
</tbody>
</table>

HUVECs (1.0x10\(^6\)) were incubated with 0, 0.1 or 1.0 \( \mu \)mol/l AngII, 1.0 \( \mu \)mol/l AngII + PDTC 15 \( \mu \)mol/l or 1.0 \( \mu \)mol/l AngII + probucol 10 \( \mu \)mol/l. Nuclear fractions were isolated and NF-κB p65 levels were measured by ELISA. Results of multiple experiments, each with duplicate or triplicate determinations, are expressed as a percentage (%) of the non-stimulated control (\( A_{450}/mg \) protein) ± standard deviation. Non-stimulated control levels were set at 100%. Statistical analysis was performed by one-way ANOVA. \( \*P<0.05 \) vs. control group, \( \#P<0.05 \) vs. 1.0 \( \mu \)mol/l AngII + PDTC group, \( \&P<0.05 \) vs. 1.0 \( \mu \)mol/l AngII + probucol group. AngII, angiotensin II; HUVECs, human umbilical vein endothelial cells; PDTC, pyrrolidine dithiocarbamate.
of these cells, we observed an increase in p65 levels following treatment with AngII, which was also inhibited by PDTC or probucol treatment (Table I).

**Effect of AngII on total SOD activity and MDA and BMP-2 protein levels in the HUVEC culture.** The effects of AngII on SOD activity and BMP-2 expression are shown in Fig. 3. Fig. 3A and B shows that AngII significantly increased the BMP-2 protein concentration in the supernatant and the MDA concentration in the HUVEC culture, but these increases were diminished by the administration of PDTC or probucol. Fig. 3C shows that AngII reduced the total SOD activity in
the cultured HUVECs; however, this reduction was partially reversed by treatment with PDTC or probucol.

**Immunohistochemistry for expression of BMP-2 protein.** Representative slides of the immunohistochemical staining of BMP-2 protein in HUVECs (at x100) are shown in Fig. 4. Our results demonstrate a significantly higher staining of BMP-2 expression in the endochyloma of HUVECs treated with AngII (Fig. 4D and E); however PDTC or probucol treatment inhibited the BMP-2 expression (Fig. 4F and G).

**Discussion**

BMP-2 is significantly involved in vascular development and pathophysiological processes. Mice genetically engineered to be deficient in BMP-2 die between days 7 and 10 of gestation due to cardiac defects prior to bone formation, which suggests the significance of BMP-2 in vascular development (16). AngII has been demonstrated to be critical in the initiation and progression of atherosclerosis. It stimulates atherosclerosis through various processes, including endothelial dysfunction, cellular proliferation, and inflammation. AngII elicits the production of superoxide anion, a reactive oxygen species, and cellular proliferation (12,13). A study by Csizsar et al indicated that vascular BMP-2 expression is regulated by the H2O2-mediated activation of NF-κB evoked by inflammatory stimuli or by high intravascular pressure (1); therefore, we hypothesized that AngII activates BMP-2 expression via NF-κB activation. Indeed, our study demonstrated that the administration of AngII significantly increased BMP-2 expression. The hypothesis was also supported by the detection of NF-κB activation. Our results revealed significantly higher levels of NF-κB p65 protein expression in the nuclei of the AngII-treated cells, which were reduced by treatment with PDTC or probucol. These findings suggest that the suppression of AngII-induced BMP-2 expression by probucol may involve the inhibition of NF-κB activation. The activation of NF-κB may be an important signal transduction pathway affecting the AngII-induced increase in BMP-2 expression.

In the current study, we specially investigated probucol, a cholesterol-lowering drug with potent antioxidant properties and a clear radical-scavenging function (19). It was originally developed as a hypolipidemic drug (20), but interest has subsequently been focused on its potent antioxidant properties. Probucol has been shown to reduce the extent of atherosclerotic lesions in animal models and to inhibit atherosclerosis and restenosis following percutaneous transluminal coronary angioplasty (21,22). Our study demonstrated that probucol inhibited the activation of NF-κB by AngII in HUVECs, which is the likely mechanism responsible for the AngII-induced BMP-2 expression.

In order to evaluate the oxidative status of the HUVECs, we detected the activity of SOD together with the level of MDA, a well-known marker of oxidative stress. We observed that AngII increased MDA levels and decreased the total SOD activity. These findings indicated that excessive oxidative stress occurred during the AngII stimulation process. However, probucol treatment significantly reduced the MDA concentration and increased total SOD activity, suggesting that probucol had potent antioxidant properties, which is supported by a previous study (23). The protective effect of probucol against atherosclerosis may partly be due to its ability to lower MDA concentrations or increase antioxidant enzyme activities (24).

These findings further suggest that oxidative stress is a common mediator of such effects and indicate that the activation of NF-κB is a significant signal transduction pathway affecting the AngII-induced increase in BMP-2 expression. The AngII-induced inhibition of BMP-2 expression may contribute to the understanding of the initiation and progression of atherosclerosis and may lead to a new therapeutic strategy.

**Acknowledgements**

This study was funded by the Beijing Science and Technology New Star Program.

**References**


